Tech Company Financing Transactions

Caldera Therapeutics Funding Round

On 1/14/2026, Caldera Therapeutics raised $112.5 million in Series A funding from Janus Henderson Investors, Omega Funds and Wellington Management Company.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

300 Technology Square 8th Fl
Cambridge, MA 02139
US

Phone

Undisclosed

Website

www.calderatx.com

Email Address

[email protected]

Overview

Caldera Therapeutics is a clinical stage company developing CLD-423, a first-in-class bispecific antibody targeting the clinically validated IL-23p19 and TL1A pathways for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases. Supported by leading biotech investors Atlas Venture, LAV, venBio, Omega Funds, Wellington Management and Janus Henderson Investors, Caldera has assembled a senior leadership team with deep experience in the discovery and development of IBD therapeutics and a proven track record of building biotechnology companies through to successful exits.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Praveen Tipirneni

        

Browse more venture capital transactions:

Prev: 1/14/2026: Vivere Oncotherapies venture capital transaction
Next: 1/14/2026: Tive venture capital transaction

Share this article

About Our VC Transactions Data

We do our best to document funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary